Assembly Biosciences Shares Soar Premarket on Gilead Pact
By Colin Kellaher
Shares of Assembly Biosciences more than doubled in premarket trading Tuesday after the biotechnology company inked a collaboration deal potentially worth hundreds of millions of dollars with Gilead Sciences.
As part of the 12-year agreement, Assembly is receiving an upfront payment of $100 million from Gilead, including $85 million in cash and a $15 million equity investment at $1.16 a share, a 60% premium to Monday's closing price of 72.6 cents.
The initial purchase gives Gilead a 19.9% stake in Assembly, which had a market capitalization of about $37.4 million based on Monday's closing price.
Assembly shares were recently up 130% to $1.67 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 17, 2023 08:29 ET (12:29 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
This Cheap Stock Is Still a Buy Even After 50% Rally
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying